GREENWICH LIFESCIENCES, INC. Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number
GREENWICH LIFESCIENCES, INC. (GLSI) reported Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number of 0 shares for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-22.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber · last filed 2023-05-22
- GREENWICH LIFESCIENCES, INC. share-based compensation arrangement by share-based payment award, accelerated vesting, number for the quarter ending 2023-03-31 was 0.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number 3 month |
|---|---|
| 2023-03-31 | 0.00 shares 10-Q · filed 2023-05-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |